Janus Henderson Group PLC Boosts Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Janus Henderson Group PLC increased its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 259.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 849,410 shares of the company’s stock after purchasing an additional 613,294 shares during the quarter. Janus Henderson Group PLC owned 2.43% of Oruka Therapeutics worth $16,415,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ORKA. JPMorgan Chase & Co. bought a new position in Oruka Therapeutics during the 4th quarter valued at about $54,000. AlphaCentric Advisors LLC purchased a new stake in Oruka Therapeutics in the fourth quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. bought a new stake in Oruka Therapeutics in the 4th quarter worth approximately $144,000. Wellington Management Group LLP grew its position in Oruka Therapeutics by 15.8% in the 4th quarter. Wellington Management Group LLP now owns 95,089 shares of the company’s stock worth $1,844,000 after purchasing an additional 12,952 shares during the period. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Oruka Therapeutics during the 4th quarter valued at $303,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Down 2.6%

ORKA stock opened at $9.46 on Friday. The business’s 50-day moving average price is $9.88 and its 200-day moving average price is $15.01. The stock has a market cap of $354.19 million, a P/E ratio of -1.51 and a beta of 0.25. Oruka Therapeutics, Inc. has a twelve month low of $5.49 and a twelve month high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. On average, equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ORKA has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Thursday. Wolfe Research started coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, February 7th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of “Buy” and an average price target of $39.86.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.